ThromboGenics, Alcon Get European Nod for Jetrea

ThromboGenics NV and its partner, the Alcon unit of Novartis AG, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Jetrea (ocriplasmin) as a treatment for vitreous macular traction, paving the way for a European launch in the second quarter.